Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:30 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 4,129 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Neck Neoplasms Clear all

Conditions: Cervical Cancer
Interventions: PET-guided Bone Marrow-Sparing Intensity Modulated Radiation Therapy (IMRT), Cisplatin, IMRT; Radiation · Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older · Female only
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2022
U.S. locations: 2
States / cities: La Jolla, California • Miami, Florida

Conditions: Esophageal Cancer, Lung Cancer, Lymphoma
Interventions: topotecan hydrochloride, low-LET electron therapy, low-LET photon therapy; Drug · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2000
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Esophageal Cancer, Gastric Cancer
Interventions: Cetuximab,Paclitaxel, Carboplatin; Drug
Lead sponsor: Brown University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Gastrointestinal Disease, Esophageal Cancer
Interventions: PET/CT (FDG PET/CT), Biomarker Testings; Procedure · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cancer, Immunotherapy, Advanced Solid Tumors Cancer, Bladder Cancer, TNBC, Triple Negative Breast Cancer, Colorectal Cancer, DMMR Colorectal Cancer, MSI-H Colorectal Cancer, Endometrial Cancer, Head and Neck Cancer, Kidney Cancer, Liver Cancer, NSCLC (Non-small-cell Lung Cancer), Skin Cancer, Melanoma (Skin Cancer)
Interventions: Biopsy; Procedure
Lead sponsor: Elephas; Industry
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2038
U.S. locations: 8
States / cities: Fort Smith, Arkansas • Frederick, Maryland • Springfield, Missouri + 4 more

Conditions: Non-melanoma Skin Cancer
Interventions: HP802-247, Bacitracin Ointment; Biological
Lead sponsor: Healthpoint; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Fatigue, Head and Neck Cancer, Psychosocial Effects of Cancer and Its Treatment, Sleep Disorders
Interventions: medical chart review, questionnaire administration, fatigue assessment and management, quality-of-life assessment; Other · Procedure
Lead sponsor: Vanderbilt University; Other
Eligibility: 21 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 3
States / cities: Nashville, Tennessee

Conditions: Mucositis, Head and Neck Cancer
Interventions: Saline, Traumeel S; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Esophageal Squamous Cell Carcinoma
Interventions: Tiragolumab, Atezolizumab, Tiragolumab Matching Placebo, Atezolizumab Matching Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 760 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 3
States / cities: Fort Myers, Florida • Wichita, Kansas • Williamsville, New York

Conditions: Esophageal Cancer
Interventions: Near Infrared Imaging; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Esophageal Cancer
Interventions: Stratafix PGA Suture; Device
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Advanced Malignancies
Interventions: Part A, Part B; Biological
Lead sponsor: TopAlliance Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 14
States / cities: Santa Monica, California • Aurora, Colorado • Miami, Florida + 9 more

Conditions: Squamous Cell Carcinoma of the Head and Neck
Interventions: Axitinib; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Nasolacrimal Duct Obstruction, Thyroid Cancer
Interventions: Artificial Tears Methylcellulose; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Cervical Cancer, Hpv, Human Papilloma Virus, HPV Infection
Interventions: Evalyn® Brush, Copan Floqswab, CHW4CervicalHealth; Device · Behavioral
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 25 Years to 65 Years · Female only
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Cervical Cancer
Interventions: CHW and Self-sampling for Cervical Cancer, Mailed Self Sampler; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 30 Years to 65 Years · Female only
Enrollment: 602 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
Interventions: Gabapentin, Methadone, Oxycodone, Quality-of-Life Assessment, Questionnaire Administration, Venlafaxine, Venlafaxine Hydrochloride Extended Release; Drug · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Locally Recurrent Head and Neck Squamous Cell Carcinoma, Locally Recurrent Hypopharyngeal Squamous Cell Carcinoma, Locally Recurrent Laryngeal Squamous Cell Carcinoma, Locally Recurrent Oral Cavity Squamous Cell Carcinoma, Locally Recurrent Oropharyngeal Squamous Cell Carcinoma, Stage II Laryngeal Cancer AJCC v8, Stage II Lip and Oral Cavity Cancer AJCC v8, Stage II Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Laryngeal Cancer AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions: Biospecimen Collection, Carboplatin, Cemiplimab, Cisplatin, Computed Tomography, Paclitaxel, Positron Emission Tomography, Radiation Therapy, Salvage Surgery; Procedure · Drug · Biological + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 115
States / cities: Tucson, Arizona • Irvine, California • Los Angeles, California + 85 more

Conditions: Cervical Cancer Screening
Interventions: Colposcopy educational material; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 21 Years and older · Female only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Human Papilloma Virus Infection
Interventions: Tailored education and referral, Staff training and patient reminders, Clinic-level reminder systems; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 9 Years to 70 Years
Enrollment: 53,414 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 2
States / cities: Alhambra, California • San Fernando, California

Conditions: Urothelial Carcinoma, Head and Neck Cancer, Melanoma, Bladder Urothelial Carcinoma
Interventions: Autologous genetically modified MAGE A10ᶜ⁷⁹⁶T cells; Genetic
Lead sponsor: Adaptimmune; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 8
States / cities: Boston, Massachusetts • St Louis, Missouri • Buffalo, New York + 4 more

Conditions: Neoplasms, Head and Neck
Interventions: Dostarlimab, Belrestotug, Nelistotug, Remzistotug; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 316 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 5
States / cities: New Haven, Connecticut • Iowa City, Iowa • St Louis, Missouri + 2 more

Conditions: Thyroid Cancer, Thyroid Carcinoma, Metastatic Thyroid Cancer, Follicular Thyroid Cancer, Unresectable Thyroid Gland Carcinoma, Papillary Thyroid Cancer
Interventions: Selpercatinib, Sodium Iodine I-131, rhTSH; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 12 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 6
States / cities: Washington D.C., District of Columbia • Tampa, Florida • Boston, Massachusetts + 3 more

Conditions: Cancer of Head and Neck
Interventions: Evidenced-based symptom management and coping intervention; Other
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

Study With Intensity Modulated Radiation Therapy With Cisplatin to Treat Stage I-IVA Cervical Cancer

Topotecan and Radiation Therapy in Treating Patients With Solid Tumors or Lymphoma

Cetuximab, Paclitaxel, Carboplatin & Radiation for Esoph, Gastroesoph & Gastric Cancer

FDG-PET-CT and Biomarkers in Esophageal Cancer

Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)

Healing Effects of HP802-247 Versus Antibiotic Ointment in Mohs Micrographic Surgery Patients

Insomnia in Patients Undergoing Chemotherapy and Radiation Therapy for Head and Neck Cancer

A Trial of Homeopathic Medication TRAUMEEL S for the Treatment of Radiation-Induced Mucositis

A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy

NIR-Guided Sentinel Lymph-Node Mapping for Esophageal Cancer

Intrathoracic Esophagogastric Anastomosis After Robot Assisted Minimally Invasive Esophagectomy Using STRATAFIX

Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies

Expansion Trial for Axitinib In Head And Neck Cancer

Artificial Tears to Prevent Nasolacrimal Duct Obstruction in Patients Treated With Radioactive Iodine for Thyroid Cancer

PopSci CHW4CervixHealth

Using CHWs or Mailing Self Sampling Home Tests to Increase Cervical Cancer Screening in South Florida

Gabapentin, Methadone, and Oxycodone With or Without Venlafaxine Hydrochloride in Managing Pain in Participants With Stage II-IV Squamous Cell Head and Neck Cancer Undergoing Chemoradiation Therapy

Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer

Patient-centered Educational Material to Improve Colposcopy Adherence

Increasing Human Papillomavirus Vaccine Uptake in Low-Income, Ethnic Minority Adolescents in Los Angeles County

MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers

A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202

Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC

Palliative and Oncology Care Intervention: Symptom COACH